Fusion Antibodies plc (AIM:FAB)
London · Delayed Price · Currency is GBP · Price in GBX 14.50
+0.50 (3.57%)
Mar 5, 2026, 8:33 AM GMT
Fusion Antibodies Market Cap
Fusion Antibodies has a market cap or net worth of 17.5 million as of March 4, 2026. Its market cap has increased by 122.45% in one year.
Market Cap
17.50M
Enterprise Value
17.64M
Revenue
1.60M
Ranking
n/a
PE Ratio
n/a
Stock Price
14.50
Market Cap Chart
Since December 18, 2017, Fusion Antibodies's market cap has decreased from 27.28M to 17.50M, a decrease of -35.85%. That is a compound annual growth rate of -5.26%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 4, 2026 | 17.50M | 10.00% |
| Dec 31, 2025 | 15.91M | 135.22% |
| Dec 31, 2024 | 6.76M | 167.72% |
| Dec 29, 2023 | 2.53M | -78.42% |
| Dec 30, 2022 | 11.71M | -59.09% |
| Dec 31, 2021 | 28.62M | -9.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 18, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| ImmuPharma | 34.94M |
| Poolbeg Pharma | 28.91M |
| Arecor Therapeutics | 27.18M |
| SkinBioTherapeutics | 24.78M |
| Aptamer Group | 22.92M |
| Sareum Holdings | 21.40M |
| Oxford BioDynamics | 10.73M |
| Genflow Biosciences | 9.38M |